Authors
Michela Bezzi, Alvin J Ing, Thomas Egenod, Nicolas Guibert, Pallav L Shah, Samuel V Kemp, Felix Herth, Farzad Bashirzadeh, Ralf-Harto Hübner, Dirk-Jan Slebos, Alan Jb Kirk, Carolin Steinack, Daniel Franzen, Malgorzata Kornaszewska, James Tonkin, Karin Klooster, Guido Levi, Venere Piluso, Jonathan P Williamson, Tajalli Saghaie, Judith Maria Brock, Konstantina Kontogianni, Rocco Bilancia, Jacopo Saccomanno, Sri Radhakrishnan, Brian R Armstrong, Narinder S Shargill, Ruediger Karpf-Wissel, Kaid Darwiche
Published in
Respiration; international review of thoracic diseases. Nov 16, 2026. Epub Nov 16, 2026.
Abstract
Bronchoscopic lung volume reduction (BLVR) with endobronchial valves is effective primarily in patients without collateral ventilation (CV-), leaving limited options for patients with collateral ventilation (CV+) in the target lobe. AeriSeal, delivered bronchoscopically, may occlude collateral channels and enable subsequent valve treatment.
To prospectively evaluate whether AeriSeal can convert target lobes from CV+ to CV- status in severe emphysema, enabling subsequent treatment with Zephyr valves.
Patients with severe COPD/emphysema, fissure completeness ≥80% on quantitative CT, and Chartis-confirmed collateral ventilation-positive (CV+) status were enrolled. Eligible subjects had fissure defects involving no more than three segmental airways. AeriSeal foam (≤40 mL) was administered bronchoscopically in one or two sessions, and CV status was reassessed after 6 weeks. Subjects converting to CV- status underwent Zephyr valve placement. Primary endpoints were successful CV conversion and target lobe volume reduction (TLVR ≥350 mL) 45 days after valve implantation.
Among 101 subjects, 75/99 evaluable patients achieved CV conversion (75.8%; 95% exact CI, 66.1-83.8%). Following valve treatment, TLVR ≥350 mL was achieved in 64/72 evaluable subjects (88.9%; 95% exact CI, 79.3-95.1%), with mean TLVR of 1062.5 ± 676.2 mL at 45 days, sustained through 12 months. At 6 months, post-bronchodilator FEV₁ improved by 0.08 L, residual volume decreased by 0.49L, SGRQ improved by 6.4 points, and mMRC by 0.8 points. Common serious adverse events included post-acute inflammatory response (PAIR; 16.7%), pneumothorax (19.2% within 45 days post-valves), COPD exacerbation, and pneumonia. Three deaths occurred, including one probably valve-related.
AeriSeal effectively converts collateral ventilation status in most treated patients, enabling successful valve therapy with durable lobar volume reduction and acceptable safety.
PMID:
43037522
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0